

Sample type	Description
Pre-immunotherapy PBMCs	Collected any time before treatment begins
Post-immunotherapy PBMCs	Collected 2-16 weeks after treatment begins
Healthy PBMCs	Same donor spiked into each sample

	No. Patients	Mean age	Gender	Ethnicity	Progression free survival (months)
Non-responder	6	68	Female (83.3%) Male (16.7%)	White (83.3%) Hispanic (16.7%)	2.84
Responder	4	68.25	Female (50%) Male (50%)	White (83.3%) Black (16.7%)	n/a

FIG. 1